474 related articles for article (PubMed ID: 28970836)
1. Fructose: A Dietary Sugar in Crosstalk with Microbiota Contributing to the Development and Progression of Non-Alcoholic Liver Disease.
Lambertz J; Weiskirchen S; Landert S; Weiskirchen R
Front Immunol; 2017; 8():1159. PubMed ID: 28970836
[TBL] [Abstract][Full Text] [Related]
2. Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut-liver axis.
Delzenne NM; Knudsen C; Beaumont M; Rodriguez J; Neyrinck AM; Bindels LB
Proc Nutr Soc; 2019 Aug; 78(3):319-328. PubMed ID: 30628563
[TBL] [Abstract][Full Text] [Related]
3. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
Kirpich IA; Marsano LS; McClain CJ
Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
[TBL] [Abstract][Full Text] [Related]
4. Obesity, fatty liver disease and intestinal microbiota.
Arslan N
World J Gastroenterol; 2014 Nov; 20(44):16452-63. PubMed ID: 25469013
[TBL] [Abstract][Full Text] [Related]
5. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
[TBL] [Abstract][Full Text] [Related]
6. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics.
Geurts L; Neyrinck AM; Delzenne NM; Knauf C; Cani PD
Benef Microbes; 2014 Mar; 5(1):3-17. PubMed ID: 23886976
[TBL] [Abstract][Full Text] [Related]
7. [Physiological patterns of intestinal microbiota. The role of dysbacteriosis in obesity, insulin resistance, diabetes and metabolic syndrome].
Halmos T; Suba I
Orv Hetil; 2016 Jan; 157(1):13-22. PubMed ID: 26708682
[TBL] [Abstract][Full Text] [Related]
8. Gut microbiota and host metabolism in liver cirrhosis.
Usami M; Miyoshi M; Yamashita H
World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
[TBL] [Abstract][Full Text] [Related]
9. Gut microbiota and metabolic syndrome.
Festi D; Schiumerini R; Eusebi LH; Marasco G; Taddia M; Colecchia A
World J Gastroenterol; 2014 Nov; 20(43):16079-94. PubMed ID: 25473159
[TBL] [Abstract][Full Text] [Related]
10. Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis.
Kuraji R; Shiba T; Dong TS; Numabe Y; Kapila YL
World J Gastroenterol; 2023 Feb; 29(6):967-996. PubMed ID: 36844143
[TBL] [Abstract][Full Text] [Related]
11. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol.
Lambert JE; Parnell JA; Eksteen B; Raman M; Bomhof MR; Rioux KP; Madsen KL; Reimer RA
BMC Gastroenterol; 2015 Dec; 15():169. PubMed ID: 26635079
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.
Han R; Ma J; Li H
Front Med; 2018 Dec; 12(6):645-657. PubMed ID: 30178233
[TBL] [Abstract][Full Text] [Related]
13. Dietary fructose as a risk factor for non-alcoholic fatty liver disease (NAFLD).
Alwahsh SM; Gebhardt R
Arch Toxicol; 2017 Apr; 91(4):1545-1563. PubMed ID: 27995280
[TBL] [Abstract][Full Text] [Related]
14. [Gut microbiota and immune crosstalk in metabolic disease].
Burcelin R
Biol Aujourdhui; 2017; 211(1):1-18. PubMed ID: 28682223
[TBL] [Abstract][Full Text] [Related]
15. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.
Meroni M; Longo M; Dongiovanni P
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31689910
[TBL] [Abstract][Full Text] [Related]
16. The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review.
Carpi RZ; Barbalho SM; Sloan KP; Laurindo LF; Gonzaga HF; Grippa PC; Zutin TLM; Girio RJS; Repetti CSF; Detregiachi CRP; Bueno PCS; Mazuqueli Pereira ESB; Goulart RA; Haber JFDS
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955942
[TBL] [Abstract][Full Text] [Related]
17. Inulin intervention attenuates hepatic steatosis in rats via modulating gut microbiota and maintaining intestinal barrier function.
Yang Z; Su H; Lv Y; Tao H; Jiang Y; Ni Z; Peng L; Chen X
Food Res Int; 2023 Jan; 163():112309. PubMed ID: 36596207
[TBL] [Abstract][Full Text] [Related]
18. Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota?
Li DY; Yang M; Edwards S; Ye SQ
JPEN J Parenter Enteral Nutr; 2013 Nov; 37(6):787-93. PubMed ID: 23538296
[TBL] [Abstract][Full Text] [Related]
19. Non-alcoholic fatty liver disease, diet and gut microbiota.
Finelli C; Tarantino G
EXCLI J; 2014; 13():461-90. PubMed ID: 26417275
[TBL] [Abstract][Full Text] [Related]
20. The role of the gut microbiota in NAFLD.
Leung C; Rivera L; Furness JB; Angus PW
Nat Rev Gastroenterol Hepatol; 2016 Jul; 13(7):412-25. PubMed ID: 27273168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
